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ABSTRACT
Traumatic brain injury (TBI) is a leading cause of death and disability, especially in the younger
population. In the acute phase after TBI, patients are more vulnerable to infection, associated
with a decreased immune response in vitro. The cause of this immune paralysis is poorly under-
stood. Apart from other neurologic dysfunction, TBI also results in an increase in vagal activity.
Recently, the vagus nerve has been demonstrated to exert an anti-inflammatory effect, termed
the cholinergic anti-inflammatory pathway. The anti-inflammatory effects of the vagus nerve are
mediated by the 7 nicotinic acetylcholine receptor present on macrophages and other cytokine-
producing cells. From these observations, we hypothesize that the immune paralysis observed in
patients with TBI may, at least in part, result from augmented vagal activity and subsequent
sustained effects of the cholinergic anti-inflammatory pathway. This pathway may counteract
systemic proinflammation caused by the release of endogenous compounds termed alarmins as a
result of tissue trauma. However, sustained activity of this pathway may severely impair the
body’s ability to combat infection. Since the cholinergic anti-inflammatory pathway can be phar-
macologically modulated in humans, it could represent a novel approach to prevent infections in
patients with TBI. Neurology® 2008;70:480–485
GLOSSARY
HF high frequency; LF low frequency; LPS lipopolysaccharide; TBI traumatic brain injury; TLR toll-like receptor.
Traumatic brain injury (TBI) is a leading cause of death and disability in the developed
world. In the United States, around 1.5 million people sustain a brain injury annually, of
whom approximately 50,000 die.1,2 TBI occurs mainly in the younger population, result-
ing predominantly from motor vehicle accidents, sports injuries, falls, and acts of vio-
lence.3 Patients with TBI are more vulnerable to infection. As a result, infection is a
common and serious complication following TBI.4 A recent study reported that espe-
cially in the first 20 days after injury, the majority of patients with TBI die of sepsis or
pneumonia.5 Other workers reported that 77% of patients developed sepsis or systemic
inflammatory response syndrome in the first 7 days following TBI.6 It is thought that the
phenomenon called post-traumatic immune paralysis is responsible for the increased
chance of developing an infection in these patients.
IMMUNE PARALYSIS IN PATIENTS WITH TBI The innate immune response is the first line of defense
against invading pathogens.7 This tightly regulated system consists of a wide variety of chemokines,
cytokines, cell associated receptors, and other mediators orchestrating the initial response to infection.
The adaptive immune response is a more specific and focused system comprised of different effector
cell types such as B- and T-cells. While these two different systems evolved independently, it has
become clear that innate immune signaling plays a critical role in initiating and instructing the adaptive
immune response.8 Therefore, effects on the innate immune response presumably also alter the adap-
tive immune response. Although limited, there are experimental data concerning the systemic immune
paralysis observed in patients with brain trauma. After severe head injury, decreased T-helper cell
activation, attenuated lymphokine-activated killer cell cytotoxicity, and depression of proinflamma-
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tory cytokine production (IL-2, IFN-), have been
reported.9-14 Moreover, ex vivo whole blood stim-
ulation with lipopolysaccharide (LPS) shows an
attenuated production of proinflammatory cyto-
kines TNF, IL-1, IL-6, IL-8, IFN-, and IL-12
in polytrauma patients compared to healthy con-
trols.15 Another study demonstrated decreased
TNF mRNA levels in human peritoneal macro-
phages after polytrauma, while the anti-
inflammatory cytokine IL-10 was upregulated.16
Taken together, these results suggest that the
early innate immune response, as well as the
adaptive immune response, to pathogens is atten-
uated in patients with TBI. However, the mecha-
nism underlying this immune paralysis following
brain injury remains unclear.
THE CNS AND TBI Dysfunction of the CNS has
been widely reported in patients with TBI. Many
reports focus on the non-autonomic nervous sys-
tem, such as motor deficits,17,18 while others have
evaluated the role of the autonomic nervous sys-
tem after TBI.19-21 The autonomic nervous system
comprises a collection of afferent and efferent
nerve fibers that regulate important vital func-
tions in the body, including blood pressure and
heart rate.22,23 The autonomic nervous system is
composed of two parts, the sympathetic and the
parasympathetic (vagal) part. The balance be-
tween these two subsystems, the sympathovagal
balance, generates the net effect of the autonomic
nervous system, of which heart rate is one of the
end products.21 Heart rate variability reflects the
balance between the sympathetic and the para-
sympathetic parts of the autonomic nervous sys-
tem, therefore, heart rate variability analysis is
extensively used to measure autonomic activity.24
MEASUREMENT OF AUTONOMIC NERVOUS
SYSTEM ACTIVITY Heart rate variability can be
analyzed in the time-domain, yielding normal-to-
normal (R-R) intervals or by spectral (frequency
domain) analysis of a series of R-R intervals. In
the time-domain, heart rate variability is usually
expressed as SD of R-R intervals (SDNN) or as
the SDNN index (SDNNIDX), which is the aver-
age of SDNN per specified interval.25 The spectral
analysis of R-R intervals is especially useful be-
cause a distinction can be made between low fre-
quency (LF) and high frequency (HF) components
in heart rate variability, providing information
about the interplay of sympathetic and parasym-
pathetic activity. Generally, LF spectral power
(range 0.04 to 0.15 Hz) reflects sympathetic input
while the HF power (range 0.15 to 0.4 Hz) repre-
sents parasympathetic influence.26,27 Therefore,
the HF/LF ratio represents a measure of sympa-
thovagal balance. A unique in vivo experiment
that illustrates this balance was conducted in pa-
tients with an implanted electrical vagus nerve
stimulator for the treatment of epilepsy.28 In these
subjects, HF power and HF/LF ratio were greatly
increased when the stimulator was activated, il-
lustrating that these measures are reliable indica-
tors of vagal activity in humans. Nevertheless,
caution should be taken when evaluating these
parameters because other workers have indicated
that parasympathetic outflow and other factors
such as baroreceptor activity also influence LF
power, thus stating that LF power represents a
combination of sympathetic and parasympathetic
input.29,30 Moreover, HF power can be influenced
by factors like respiratory pattern.30
HEART RATE VARIABILITY IN PATIENTS WITH
ACUTE TBI Although data are limited, a few hu-
man studies have assessed heart rate variability
after TBI in the acute phase. An increase in HF/LF
ratio was reported in the acute phase after TBI,
indicating dominance of parasympathetic activi-
ty.20,31 In these studies, increased intracranial
pressure, often present in acute TBI, has been
linked to the high HF/LF ratios observed.20,31
Along these lines, patients with acute subarach-
noid hemorrhage, which is associated with a
rapid increase in intracranial pressure,32 displayed
significantly increased HF power compared to
controls, while LF power did not change.33 These
results suggest that in patients with TBI, parasym-
pathetic (vagal) activity is augmented, resulting in
an increased HF power and increased HF/LF ratio,
and that elevated intracranial pressure may play an
important role in this process. In addition to the
above described association between TBI/increased
intracranial pressure and heart rate variability as a
measure of vagal tone in patients with TBI, a model
of increased intracranial pressure demonstrated a
direct link between intracranial pressure and vagal
tone. In cats, vagal activity, measured by microneu-
rography, was increased relative to the increase in
intracranial pressure induced by inflating a subdural
balloon.34 This suggests that high intracranial pres-
sure directly influences vagal tone. A potential
mechanism behind this phenomenonmight be com-
pression of higher vagal nuclei, or the brainstem,
leading to vigorous firing of the medulla oblongata,
the center where the vagus nerve originates.
VAGAL ACTIVITY AND THE CHOLINERGIC ANTI-
INFLAMMATORY PATHWAY Experimental evi-
dence in the past several years has demonstrated
that activation of the efferent vagus nerve has an
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inhibitory effect on the innate immune response
(the cholinergic anti-inflammatory pathway35-37).
Several in vitro studies have demonstrated that
pretreatment of cultured human macrophages
with the principal vagal neurotransmitter acetyl-
choline significantly attenuates the LPS-induced
release of proinflammatory mediators such as
TNF, IL-6, IL-1, IL-18, and HMGB1, while re-
lease of the anti-inflammatory cytokine IL-10 was
unaffected.38,39 Moreover, vagus nerve electrical
stimulation attenuates serum TNF and IL-6 lev-
els in animals after endotoxin administration and
prevents the development of shock.38,40-42 In con-
trast, vagotomized animals exhibited elevated
levels of proinflammatory cytokines with aggra-
vation of shock.38,43,44 In humans, we know of
only one study that evaluated inflammatory me-
diators in patients with a vagus nerve stimula-
tor.45 In this study, circulating inflammatory
mediators were measured before implantation of
the stimulator and after 12 weeks following im-
plantation of the stimulator in a small group of
patients with severe depression. After stimulator
implantation, the proinflammatory mediators
TNF and IL-6 were significantly elevated; how-
ever, other proinflammatory mediators such as
IL-1 and CRP were not. In addition, levels of the
anti-inflammatory cytokine TGF- were also sig-
nificantly increased, which makes it difficult to
draw any conclusions regarding the manner in
which vagus nerve stimulation modulates the im-
mune status in these patients. Moreover, levels of
circulating inflammatory mediators in these pa-
tients do not actually reflect the status of the im-
mune response, since no inflammatory stimulus
was present.
The anti-inflammatory effect of the vagus
nerve is mediated by the 7 nicotinic acetylcho-
line receptor (7nAchR) expressed on macro-
phages and other cytokine-producing cells.42 The
identification of this receptor stimulated the use
of nicotine instead of acetylcholine in studies ex-
ploring the anti-inflammatory effect of the vagus
nerve because of its higher efficiency and selectiv-
ity, and has led to the search for even more selec-
tive 7nAchR agonists.39 GTS-21, a specific
7nAchR agonist that has already been used in
human clinical trials for the treatment of AD, has
been studied in a murine pancreatitis model.
GTS-21 decreased pancreatitis severity, associ-
ated with reduced IL-6 levels and decreased pan-
creatic neutrophil accumulation.44 Furthermore,
CNI-1493, a compound exhibiting systemic anti-
inflammatory effects currently used in clinical tri-
als for the treatment of Crohn disease, has
recently been shown to activate the vagus nerve
via a centrally mediated intracerebral effect.46,47
CNI-1493 prevented endotoxin-induced shock
and attenuated the rise in serum TNF levels in
rats.46,47 Inhibitors of 7nAchR have also been
identified. Mecamylamine, a drug used in humans
for the treatment of hypertension and tobacco ad-
diction, has been utilized in experimental settings
and exhibited effects analogous to vagotomy,
such as enhanced serum IL-6 levels and aug-
mented severity of inflammation.44 The intracel-
lular cascade after 7nAchR activation has been,
in part, elucidated by a recent study demonstrat-
ing that activation of 7nAchR leads to recruit-
ment and activation of the anti-inflammatory
JAK2-STAT3 (Janus kinase-2; signal transducers
and activators of transcription-3) cascade.48
While studies regarding the cholinergic anti-
inflammatory pathway have mainly focused on
the innate immune system, the adaptive immune
response may also be attenuated by vagal outflow
because of the vital role the innate immune sys-
tem plays in initiating the subsequent adaptive
immune response.
In addition, apart from the anti-inflammatory
effects of the vagus nerve, inflammation can also
affect vagal tone. Evaluation of heart rate vari-
ability during endotoxic shock in humans demon-
strated attenuated variability accompanied by a
decrease in total spectral power.49 This may rep-
resent a negative feedback mechanism to prevent
inhibition of the immune response. In this article
we focus on the anti-inflammatory effects of the
vagus nerve.
The cholinergic anti-inflammatory response rep-
resents an exciting new pathway that modulates the
innate, and possibly also the adaptive, immune re-
sponse and provides novel pharmacologic treatment
opportunities for situations associated with a dis-
turbed sympathovagal balance.
SUMMARY AND HYPOTHESIS In this report we
have discussed three separate observations. 1)
The immune response is severely impaired in pa-
tients after TBI, and is likely to be associated with
the high prevalence of infections in these patients.
2) In the acute phase after TBI, vagal activity is
augmented, resulting in a shift in the sympathova-
gal balance, possibly as a consequence of in-
creased intracranial pressure. 3) Vagal activity
has an inhibiting effect on the innate immune re-
sponse. These observations have led us to a new
hypothesis that could explain the immune paraly-
sis observed in patients with TBI. We hypothesize
that the impaired immune response in these sub-
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jects may, at least in part, result from increased
vagal activity and subsequent suppression of the
immune response (figure).
DISCUSSION The hypothesis postulated above is
based on evidence obtained from studies with dif-
ferent research objects. To our knowledge, no
studies are available that test this hypothesis di-
rectly. Since the cholinergic anti-inflammatory
pathway can be pharmacologically modulated in
humans, such treatment in patients with TBI
could represent a novel, promising approach to
prevent infections in this specific group of pa-
tients.
Although elevated intracranial pressure ap-
pears to be an important link in the parasympa-
thetic anti-inflammatory response following TBI,
other mechanisms have also been suggested. Re-
cently, the role of endogenous mediators in sys-
temic inflammation in the absence of infection50
was discussed. Toll-like receptors (TLRs) are
well-known for their role in recognition of exoge-
nous pathogens and subsequent triggering of im-
mune responses. Excessive or inappropriate
activation of TLRs can lead to systemic inflam-
mation and shock, similar to that observed in sep-
tic patients. In addition to recognizing outside
invaders, TLRs, as well as other receptors, also
recognize endogenous damage signals termed
alarmins, such as heat-shock proteins and
HMGB1. Tissue trauma, for instance resulting
from TBI, elicits release of these damage
signals.51-53 Consequently, trauma can trigger the
immune response and this could explain the sys-
temic inflammatory reaction in the absence of in-
fection often observed in these patients. An
increase in vagal activity may counteract this
mechanism by attenuating the release of endoge-
nous inflammatory mediators. In this context, it
is noteworthy that ex vivo treatment of human
monocytes with nicotine (stimulation of the cho-
linergic anti-inflammatory pathway) resulted in
downregulation of TLR4 expression in human
monocytes.54 This observation may also explain
the attenuated production of proinflammatory
cytokines in blood of trauma patients that was
stimulated ex vivo with LPS, the primary ligand
for TLR4.15 In this prospect, increased vagal ac-
tivity may represent a negative feedback mecha-
nism counteracting the massive systemic
proinflammatory response. This notion is sup-
ported by animal studies in which increased vagal
activity resulted in attenuation of inflammation,
prevention of development of shock, and de-
creased mortality after experimental inflamma-
tion.38,39,44 In this view, the resultant and sustained
immune paralysis is merely a side-effect of the
negative feedback loop. However, the animal
studies mentioned before have all been performed
using models of sterile inflammation. In animal
experiments using live microbial sepsis, activa-
tion of the cholinergic anti-inflammatory path-
way resulted in worsened survival, impaired
migration of neutrophils to the inflamed area,
and increased outgrowth of bacteria.40,43,55 More-
over, human data on heart rate variability in the
acute phase after TBI indicates that increased
HF/LF ratios are associated with poor outcome
and higher mortality.31,56,57 These results suggest
that increased vagal activity is beneficial in sterile
inflammation induced by LPS or chemical com-
pounds that evoke inflammation, but may impair
the body’s ability to combat an infection with live
bacteria.
In contrast to aforementioned studies, also a
decreased HF power and decreased HF/LF ratios
have been reported in patients with TBI.19,21,58
However, these studies evaluated patients in the
post-acute (chronic) phase of TBI (30 days).
Along these lines, patients in the chronic phase of
subarachnoid hemorrhage demonstrated similar
HF/LF ratios compared to control subjects, while
HF/LF ratios were increased in the acute phase, as
discussed before.33 In the chronic phase of TBI or
subarachnoid hemorrhage, patients usually do
Figure Traumatic brain injury and vagal activity
Traumatic brain injury increases vagal tone directly or as a
result of elevated intracranial pressure. Subsequently, vagal
activity attenuates inflammation via the cholinergic anti-
inflammatory pathway. As a result, susceptibility toward in-
fections increases, resulting in worse outcome.
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not have an increased intracranial pressure, possi-
bly explaining the absence of increased vagal ac-
tivity. Moreover, a potential explanation for
decreased vagal output in the chronic phase of
TBI may be damage to the brainstem and medulla
oblongata resulting in impaired activity of the va-
gus nerve. In the acute phase of TBI, this effect
may be overwhelmed by vigorous firing as a con-
sequence of the compression of the brainstem.
One study in a very acute setting (immediately af-
ter admission to the intensive care unit one
5-minute ECG was recorded) also reported de-
creased vagal activity and lower HF/LF ratios, in-
dicating sympathetic dominance.59 However, in
this very acute setting, elevated intracranial pres-
sure has probably not developed yet. Thus, time
after injury appears to be a very important factor
in autonomic dysfunction.
Taken together, we believe that our hypothesis
may, at least in part, explain the immune paraly-
sis observed in the first phase following TBI.
Since increased vagal tone is associated with in-
creased mortality and poor outcome in patients
with TBI, intervening in the cholinergic anti-
inflammatory pathway could be of potential ben-
efit to these patients. This possibility warrants
further research to elucidate the mechanism of
immune paralysis in patients with TBI.
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